EN
FR
Contact Us
Donate

Lymphoma
Patient Experience
Resources
News & Events
Get Involved
Ways to Give
About Us
Know Your Nodes

Lymphoma
Patient Experience
Resources
News & Events
Get Involved
Ways to Give
About Us
Know Your Nodes

News

pCODR Final Recommendation Issued for ibrutinib (Imbruvica) for First-line Treatment of CLL

News Research

pCODR Final Recommendation Issued for ibrutinib (Imbruvica) for First-line Treatment of CLL

pCODR Final Recommendation Issued for ibrutinib (Imbruvica) for Mantle Cell Lymphoma (MCL)

News Research

pCODR Final Recommendation Issued for ibrutinib (Imbruvica) for Mantle Cell Lymphoma (MCL)

Health Canada Approves Venetoclax for CLL Patients With 17P deletion or if No Other Treatment Options are Available

News Research

Health Canada Approves Venetoclax for CLL Patients With 17P deletion or if No Other Treatment Options are Available

Lymphoma Canada 2016 Research Fellowship Award

News Research

Lymphoma Canada 2016 Research Fellowship Award

Creighton Classic – Par for the Cure – Golf Tournament

News

Creighton Classic – Par for the Cure – Golf Tournament

CLL/SLL Patient Survey survey

News

CLL/SLL Patient Survey

Tired of Cancer App

News

Tired of Cancer App

Coping with Cancer – Mindfulness Webinar masthead_ph_leaves

News Presentations

Coping with Cancer – Mindfulness Webinar

Waldenstrom’s Macroglobulinemia Patient & Caregiver Surveys

News

Waldenstrom’s Macroglobulinemia Patient & Caregiver Surveys

Health Canada Approves ibrutinib for Waldenström’s Macroglobulinemia

News Research

Health Canada Approves ibrutinib for Waldenström’s Macroglobulinemia

Search

Are you a patient?

Get Informed

Are you a healthcare professional?

See Resources

Contact Us

Lymphoma Canada
6860 Century Avenue, Suite 202
Mississauga, ON L5N 2W5
Telephone 905.858.5967
Toll Free: 1.866.659.5556
General inquiries: info@lymphoma.ca
Charitable Number: 873461040RR0001

Donate

With your support, no one will have to face lymphoma alone. You can make a difference!
Donate

Careers

Join Our Mailing List

First Name *

Last Name *

Email Address *

Preferred Language

English
French

YouTube
X
Facebook
Instagram
LinkedIn

Donate
Accessibility
Privacy Policy
Terms of Use

Close Menu

Lymphoma
Patient Experience
Resources
News & Events
Get Involved
Ways to Give
About Us
Know Your Nodes

EN
FR
Contact Us
Donate

News

pCODR Final Recommendation Issued for ibrutinib (Imbruvica) for First-line Treatment of CLL

Search

Recent Posts

Are you a patient?

Are you a healthcare professional?

Contact Us

Donate

Join Our Mailing List